Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists
- PMID: 2894467
- DOI: 10.1021/jm00398a028
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists
Abstract
A rational approach to the design of centrally acting agents is presented, based initially upon a comparison of the physicochemical properties of three typical histamine H2 receptor antagonists which do not readily cross the blood-brain barrier with those of the three brain-penetrating drugs clonidine (6), mepyramine (7) and imipramine (8). A good correlation was found between the logarithms of the equilibrium brain/blood concentration ratios in the rat and the partition parameter, delta log P, defined as log P (1-octanol/water)-log P (cyclohexane/water), which suggests that brain penetration might be improved by reducing overall hydrogen-bonding ability. This model has been employed as a guide in the design of novel brain-penetrating H2 antagonists by the systematic structural modification of representatives of different structural types of H2 antagonists. Although marked increases in brain penetration amongst congeners of cimetidine (1), ranitidine (9), and tiotidine (10) were achieved, no compound was found with an acceptable combination of H2 antagonist activity (-log KB in the guinea pig atrium greater than 7.0) and brain penetration (steady-state brain/blood concentration ratio greater than 1.0). Conversely, structural modification of N-[[(piperidinyl-methyl)phenoxy]propy]acetamide (30) led to several potent, novel compounds which readily cross the blood-brain barrier. One of these, zolantidine (SK&F 95282, 41), whose -log KB is 7.46 and steady-state brain/blood ratio is 1.4, has been identified for use in studying histaminergic H2 receptor mechanisms in brain. Comparison of delta log P values with the logarithms of the brain/blood ratios for 20 structurally diverse compounds for which data became available confirms a highly significant correlation and supports the general validity of this model.
Similar articles
-
Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist.Br J Pharmacol. 1988 Jan;93(1):69-78. doi: 10.1111/j.1476-5381.1988.tb11406.x. Br J Pharmacol. 1988. PMID: 2894879 Free PMC article.
-
Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity.Br J Pharmacol. 1996 Aug;118(7):1813-21. doi: 10.1111/j.1476-5381.1996.tb15608.x. Br J Pharmacol. 1996. PMID: 8842448 Free PMC article.
-
A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.J Pharmacol Exp Ther. 1983 Jan;224(1):171-9. J Pharmacol Exp Ther. 1983. PMID: 6129316
-
Chemical and biologic differences between various H2-receptor antagonists.Scand J Gastroenterol Suppl. 1988;146:73-7. doi: 10.3109/00365528809099133. Scand J Gastroenterol Suppl. 1988. PMID: 2906470 Review.
-
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004. Clin Pharmacokinet. 1991. PMID: 1673880 Review.
Cited by
-
Synthesis and preclinical evaluation of [11C]uPSEM792 for PSAM4-GlyR based chemogenetics.Sci Rep. 2024 Jan 22;14(1):1886. doi: 10.1038/s41598-024-51307-0. Sci Rep. 2024. PMID: 38253691 Free PMC article.
-
A facile tert-butyl nitrite-assisted preparation of deamino graphitic carbon nitride (DA-gCN) as a photocatalyst for the C-H arylation of heteroarenes using anilines as radical source.Turk J Chem. 2023 Aug 29;47(5):1195-1208. doi: 10.55730/1300-0527.3605. eCollection 2023. Turk J Chem. 2023. PMID: 38173759 Free PMC article.
-
The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery.Pharmaceutics. 2023 Nov 12;15(11):2619. doi: 10.3390/pharmaceutics15112619. Pharmaceutics. 2023. PMID: 38004597 Free PMC article. Review.
-
Candidate Tracers for Imaging Colony-Stimulating Factor 1 Receptor in Neuroinflammation with Positron Emission Tomography: Issues and Progress.ACS Pharmacol Transl Sci. 2023 Oct 18;6(11):1632-1650. doi: 10.1021/acsptsci.3c00213. eCollection 2023 Nov 10. ACS Pharmacol Transl Sci. 2023. PMID: 37974622 Review.
-
Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer.J Med Chem. 2023 Nov 23;66(22):15477-15492. doi: 10.1021/acs.jmedchem.3c01669. Epub 2023 Nov 7. J Med Chem. 2023. PMID: 37934858 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources